Celularity vs Elutia
CELU and ELUT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CELU and ELUT compare
Elutia is the larger company, worth 1.8 times as much as Celularity ($36.3M against $20.4M).
Elutia grew revenue faster over the last twelve months (79.4% versus −58.1% for Celularity).
Elutia keeps more of each dollar of sales as profit, with a net margin of 321% compared with −246% at Celularity.
Elutia scores higher on the StockData Score (8 against 7 for Celularity), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CELU | ELUT |
|---|---|---|
| Size and price | ||
| Market cap | $20.4M | $36.3M |
| Share price | $0.630 | $0.820 |
| Change, 1 year | −62.5% | 10.8% |
| Change, 5 years | −99.1% | −85.9% |
| Beta (5Y) | 1.93 | 0.25 |
| Employees | 115 | 26 |
| StockData Score | ||
| Total score | 7 | 8 (better) |
| Valuation score | 1 | 2 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 1 | 2 (better) |
| Health score | 4 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.1× (better) | 2.1× |
| P/B | – | 2.4× |
| FCF yield | – | −140% |
| Fair value | – | $1.05 |
| Margin of safety | – | 21.9% |
| Growth | ||
| Revenue growth (TTM) | −58.1% | 79.4% (better) |
| Revenue growth, 5Y average | 13.2% (better) | −22.0% |
| Profitability | ||
| Gross margin | 19.2% | 57.7% (better) |
| Operating margin | −264% | −152% (better) |
| Net margin | −246% | 321% (better) |
| FCF margin | – | −299% |
| Financial health | ||
| Debt / equity | – | 0.53 |
| Current ratio | 0.11 | 2.63 (better) |
| Altman Z-score | −16.48 | −5.70 (better) |
| Piotroski F-score | 1 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 6.8% | 39.8% |
| Held by insiders | – | 52.0% |
| Insider net buying, 12 months | – | $212K |
| Short interest, % of float | – | 0.16% |
Go deeper
- CELU stock overview
- CELU income statement
- CELU valuation and score
- ELUT stock overview
- ELUT income statement
- ELUT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.